Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity鈥檚 filings don鈥檛 read like a traditional tech company; every page weaves HIPAA obligations, clinician engagement metrics, and life-science ad revenue into one dense narrative. If you need the Doximity annual report 10-K simplified or want to see how tele-health adoption shifts quarter-to-quarter inside a Doximity quarterly earnings report 10-Q filing, you鈥檙e in the right place.
Stock Titan applies AI models built for regulatory language, understanding Doximity SEC documents with AI so you don鈥檛 have to. We tag risk factors, pull out user-growth charts, and alert you to Doximity insider trading Form 4 transactions within minutes of submission. Whether it鈥檚 a sudden product-launch 8-K or the annual Doximity proxy statement executive compensation, our platform delivers context alongside the raw text.
Use cases our members rely on every day:
- Instant push notifications for Doximity Form 4 insider transactions real-time and other executive stock moves.
- Side-by-side redlines that make a Doximity earnings report filing analysis a two-minute task, not an afternoon.
- One-click highlights that turn 鈥淩isk Factors鈥� into an at-a-glance checklist, making Doximity 8-K material events explained in plain English.
From Doximity executive stock transactions Form 4 to the next Doximity SEC filings explained simply, every document flows into our real-time feed, fully searchable and linked to prior periods. Spend less time hunting through EDGAR and more time acting on clear, AI-powered insights.
Walgreens Boots Alliance, Inc. (WBA) 鈥� Form 4 filing dated 07/11/2025
Director Robert Luther Huffines reported a grant of 2,158.89 phantom stock units on 07/09/2025 under the company鈥檚 Amended & Restated 2021 Omnibus Incentive Plan. Phantom stock units are cash-settled instruments that mirror the economic value of one share of common stock but do not convey voting rights. The award was coded 鈥淎,鈥� indicating an acquisition (grant) rather than an open-market transaction.
The units carry an implied value of $11.58 each, matching the reference price disclosed in the derivative table, for an aggregate notional value of roughly $25,000. Following this grant, Huffines鈥� total holding increased to 29,992.26 phantom units, all held directly. According to plan terms, settlement occurs after he ceases to serve as a director, aligning his long-term economic interests with shareholders.
No common stock, options, or other instruments were bought or sold, and there were no dispositions. The filing contains no amendments, no 10b5-1 trading plan notation, and no indicators of material corporate developments beyond routine director compensation.
The filing is a Form 144 notice covering a proposed insider sale of Doximity, Inc. (DOCS) common stock.
- Seller: Regina M. Benjamin (relationship to issuer not specified).
- Shares to be sold: 5,000 common shares.
- Aggregate market value: US $300,200.
- Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Approximate sale date: 11 July 2025 on the NYSE.
- Shares outstanding: 187,826,153, making the proposed sale about 0.0027 % of outstanding shares.
- Source of shares: Acquired via stock-option exercise on 11 July 2025; paid in cash.
- Prior sales: The seller disposed of 10,000 shares on 25 June 2025 for gross proceeds of US $600,000.
No additional financial metrics, earnings figures, or strategic information are provided. The notice is routine and does not appear material to Doximity鈥檚 capital structure or operations.
Form 4 filing for Y-mAbs Therapeutics (YMAB) discloses that director Laura Hamill received new equity awards on 30 June 2025.
- Restricted Stock Units: 25,080 RSUs granted at no cost. The award vests in full on the earlier of 12 months after grant or immediately before the 2026 annual shareholder meeting, subject to continued service.
- Stock Options: 33,450 options with a US$4.51 exercise price, expiring 30 June 2035. Vest in equal monthly instalments over one year and become exercisable upon vesting.
- Post-transaction ownership: Hamill now directly holds 30,905 YMAB common shares and 33,450 vested/unvested options.
The transactions reflect routine director compensation under the 2018 Equity Incentive Plan and do not involve open-market purchases or sales.
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) filed seven Post-Effective Amendments on Form S-8 to deregister all unsold shares previously registered for issuance under its 2019 employee equity plans. The action follows the closing of its merger with Merck KGaA, Darmstadt, Germany on 1 July 2025, under which SpringWorks became a wholly owned subsidiary of Merck through EMD Holdings Merger Sub, Inc.
The amendments cover the following historical S-8 registrations:
- Reg. Nos. 333-234365, 333-237350, 333-253531, 333-262996, 333-270096, 333-277380 and 333-285076.
- In aggregate, these filings had registered tens of millions of common shares for the 2019 Stock Option & Incentive Plan, the Amended & Restated 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan.
Because the company is now private, SpringWorks has terminated all offerings under these plans. Consistent with undertakings in each registration statement, any securities that remained unsold as of the merger date are withdrawn from registration. The filing is signed on behalf of the company by Secretary Michael MacDougall and relies on Rule 478 of the Securities Act to omit additional signatures.
The amendments are largely administrative, signalling the end of SpringWorks鈥� status as an independent public issuer and the cessation of share issuance under its legacy equity compensation and ESPP programmes.
Doximity (NYSE:DOCS) filed a Form 4 revealing that director Regina M. Benjamin exercised 10,000 stock options at $2.21, converted the resulting Class B shares into Class A, and immediately sold those 10,000 Class A shares at $60 on 06/25/2025. The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 02/26/2025.
The gross proceeds total roughly $600,000, representing about 38% of Benjamin鈥檚 direct Class A position before the sale. After the transactions she still directly owns 16,618 Class A shares and holds 371,138 option shares.
Doximity (NYSE:DOCS) director Timothy S. Cabral filed Form 4 reporting a same-day option exercise and sale on 06/25/2025.
Cabral converted 10,000 Class B shares into Class A at a $2.21 strike, then sold the entire block at $60.00 per share under a Rule 10b5-1 plan adopted 02/13/2025, generating roughly $600,000 in gross proceeds. His direct Class A holdings fell from 16,360 to 6,360 shares, a 61% reduction. No additional acquisitions or new compensation arrangements were disclosed.
Form 144 Notice of Proposed Sale filed for Doximity (NYSE: DOCS) indicates an insider sale transaction. Timothy Cabral plans to sell 10,000 shares of common stock with an aggregate market value of $600,000, to be executed through Morgan Stanley Smith Barney LLC.
Key transaction details:
- Securities were acquired through stock option exercise on June 25, 2025
- Sale represents a small fraction of total outstanding shares (187,826,153)
- Planned execution date: June 25, 2025
- Previous sale by the same insider: 10,000 shares sold on May 23, 2025 for $505,796
This Form 144 filing represents a declaration of intent to sell securities and confirms the seller has no knowledge of undisclosed material adverse information regarding Doximity's operations.
The Form 144 filing submitted on behalf of Doximity, Inc. (DOCS) discloses a proposed sale of 10,000 common shares through broker Morgan Stanley Smith Barney LLC. The shares鈥攁cquired via a stock-option exercise on 06/25/2025鈥攃arry an aggregate market value of $600,000. With 187,826,153 shares outstanding, the transaction represents roughly 0.005 % of total shares, indicating an immaterial dilution impact. The seller reported no prior sales in the last three months and affirmed awareness of no undisclosed adverse information. The planned sale is scheduled for on or after 06/25/2025 on the NYSE under Rule 144, reflecting routine insider liquidity while complying with SEC disclosure requirements.
FAQ
What is the current stock price of Doximity (DOCS)?
What is the market cap of Doximity (DOCS)?
What is the core business of Doximity Inc?
How does Doximity ensure the security and privacy of its users?
What features make Doximity stand out in the healthcare industry?
Who are the primary users of Doximity?
How does Doximity generate revenue?
How does Doximity compare to traditional professional social networks?
Is Doximity accessible on mobile devices?
What role does Doximity play in enhancing patient care?
